TRANSLATING INNOVATIVE HEALTH SCIENCE INTO REVOLUTIONARY PRODUCTS

Jupiter Wellness

Explore Now

Scientifically Backed PRODUCTS WITH PURPOSE

icon

ECZEMA

JW-100 - Topical treatment of Atopic Dermatitis .

icon

BURNS

JW-300 - Topical treatment of first-degree burns and sun exposure.

icon

COLD SORES

JW-400 - Topical treatment of herpes labialis (cold sores).

icon

JELLYFISH PROTECTION SUNSCREEN

NoStingz - Topical protection from Jellyfish, sea lice, and UV Rays.

icon

HAIR LOSS

Minoxidil Booster - Topical treatment improves Minoxidil efficacy

icon

Psoriasis and Vitiligo

Photocil - Topical treatment for psoriasis and vitiligo.

Try on the touch

Watch Video Presentation

App itself is fast, fluid and loads quickly.

Jupiter Wellness, Inc. (NASDAQ: JUPW) Digital Dividend is Causing a Short Squeeze; Really Strong Chart; Rising Revenues just Announced in this Multi-Product Bio Pharmaceutical and Wellness Company; $JUPW

  • Digital Dividend released Overseas will continue this Short Squeeze of epic proportions. Virtually Impossible to cover short positions.
  • Active Research Programs Developing Multiple Health & Wellness Product Lines.
  • Growing Revenues from Consumer Products, Contract Research and Licensing.
  • New BOD Member Appointed who Reported Insider Purchase of 122,000 Shares.
  • Exclusive Licensing Agreement with Rejoy, Inc. to Develop Products for the Treatment of Nipple Neuropathies and Sexual Problems in Women with Cancer.
  • Notice of Allowance for Patent Titled “Minoxidil Adjuvant Therapies.”
  • Clinical Trial Comparison of JW-100 and EUCRISA for the Treatment of Eczema.
  • JUPW Shares Currently Considered Over-Sold & Over-Shorted by Watch Groups.

Jupiter Wellness, Inc. (NASDAQ: JUPW) is a diversified company that supports health and
wellness by researching and developing over-the-counter (OTC) products and intellectual property.
The JUPW product pipeline addresses a range of conditions, including hair loss, eczema, burns, and
sexual wellness. Revenue is generated through the sales of OTC and consumer products, contract
research agreements, and licensing royalties.
Buyins.net, a service which tracks investor shorting in public companies, reports that JUPW has
been experiencing substantial short selling activity over the past several weeks. Data from mid-
September through early-November indicate that over 216 million shares were sold short during this
time period, placing unusually strong downward pressure on the JUPW pps. These short sold shares
must be covered at some point and Buyins.net is projecting a potential short squeeze for JUPW could
occur in the near future.
StockWireNews has also been tracking JUPW in recent weeks and is currently alerting its followers
to the potential for JUPW to jump in share price as a result of multiple positive catalysts from
the company as well as the current over-sold and potentially over-shorted
condition of JUPW shares in the markets.

Third Quarter Revenues in 2022 Jump to $1,569,925 Compared to Revenues of $687,928 in Third Quarter of 2021

On November 14th JUPW announced its financial results for the Third Quarter ended September 30, 2022. JUPW generated $1,569,925 in revenues for the three months that ended September 30, 2022, compared to $687,928 for the same period in 2021. In addition to the revenues booked in the Third Quarter, JUPW wholly-owned subsidiary, SRM Entertainment,
received $3.6 million in guaranteed purchase orders from the world’s largest amusement parks. These revenues will be realized once the orders are shipped from our facilities.
Brian John, CEO of JUPW, said, “I am very pleased with our progress in reducing our operating expenses while increasing our revenues. We anticipate continued revenue growth and reduced expenses as the demand for our products and services grows steadily. With combined sales orders shipped or received in the Third Quarter of over $5 million just coming off a record revenue in the Second Quarter, we are well on our way toward profitability by mid-2023.” John continued, “We plan to file to spin off our SRM division to our shareholders as its own separate NASDAQ traded company by year-end. Jupiter Wellness will remain the largest shareholder while enabling us to access additional capital to grow the SRM business at a faster pace.”

Highlights in Third Quarter

Dr. Skender Fani, the Chairman of Otis Elevator-Austria, Heim GmbH, was appointed to the JUPW Board of Directors. On November 1, Dr. Fani filed a Form 4 reporting the purchase of 122,000 shares.
JUPW signed an exclusive licensing agreement with Rejoy, Inc., a California Corporation, to develop prescription products for the treatment of nipple neuropathies and associated sexual problems in women that have been treated for breast cancer.
The United States Patent and Trademark Office granted a notice of allowance for patent application No. 16/747,685, titled “Minoxidil Adjuvant Therapies.”

JUPW Re-Opens Enrollment in Clinical Trial Comparison of JW-100 and EUCRISA for the Treatment of Eczema
Expected to Complete Patient Enrollment of Clinical Trial in December 2022

On November 10th JUPW announced that it has re-opened enrollment in a clinical trial aimed at evaluating the superiority of JW-100, a novel cannabidiol topical cream, in a head-to-head study against EUCRISA, an FDA Approved topical treatment for eczema developed by Pfizer.
The study was put on hold to solve stability issues in the original JW-100 formulation. These issues were addressed and resolved to the satisfaction of the study’s clinical investigators.
JUPW CEO Brian John, said “Due to the nature of a double-blind study, we are only able to access certain data from the first run of this trial. However, what we have seen suggests to our team of scientists that we are on the right track and that this study warrants continuation. We are very encouraged by this update and hope to prove that our JW-100 is as effective, if not superior to a leading drug already on the market that does hundreds of millions in revenue. We hope to have the second half of this trail completed in the first quarter of 2023.”

Plan to Spin Off Caring Brands, Inc. as Digital Securities Dividend to JUPW Shareholders

On November 7th JUPW announced that it has plans to transfer and spin-off forty percent (40%) of the Company’s wholly-owned subsidiary, Caring Brands, Inc., by way of a dividend in the form of digital securities to JUPW shareholders with a record date to occur in late November. JUPW will maintain sixty percent (60%). The spin-off transaction will be subject to various
conditions, including Caring Brands, Inc. meeting the qualifications for future listing on the Blockchain-powered Securities Exchange Upstream, the revolutionary trading app for digital securities and NFTs powered by Horizon Fintex (“Horizon”) and MERJ Exchange Limited (“MERJ”). Management’s intention is to publicly list Caring Brands, Inc. via a listing on Upstream in December 2022.
Caring Brands, Inc. is an innovative developer of cannabidiol (CBD) based therapeutics and wellness products. The Company’s inventory of CBD-enhanced skin-care therapeutics addresses a range of indications including skincare and general wellness. The Company generates revenue through the manufacturing, distribution, and marketing of a diverse line of consumer products infused with CBD.
The planned dual listing on Upstream is designed to provide Caring Brands, Inc. the opportunity to access a global, digital-first investor base that can trade using USDC digital currency along with credit cards, debit cards, PayPal, and USD, unlocking liquidity and enhancing price discovery while globalizing the opportunity to invest in Caring Brands, Inc. Once approved for listing on Upstream, JUPW shareholders of record will be able to install the Upstream App and receive the dividend shares. Details on how shareholders of record will receive their dividend shares and how to trade them on Upstream will be explained upon notification of the dividend’s record date.

NASDAQ CHART

TRADINGVIEW SNAPS

Learn more about Jupiter Wellness Today

Click to find out more

no obligation

map

Get in touch.

Write us a message

We are available. Please send us a message.

DISCLAIMER: CAP/FrontPageStocks/CorporateAds.com (CA) is a third-party publisher and news dissemination service provider. CAP/FPS/CA is NOT affiliated in any manner with any company mentioned herein. CAP/FPS/CA is a news dissemination solutions provider and is NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. CAP/FPS/CA’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. CAP/FPS/ CA is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. CAP/FPS/CA has been compensated $2500 by a third party for dissemination of this article.